22q11.2 distal deletion syndrome

Lore & Background

22q11.2 distal deletion syndrome occurs spontaneously, with no known environmental cause; the genetic term is de novo, and both parents typically have normal chromosomes. The deletion is thought to arise from a mistake during the formation of sperm or egg cells, when chromosomes pair up and swap segments. Similar DNA sequences can mismatch, leading to unequal crossing over that loops out and excises a length of chromosome.

Every deletion is unique, and each person may have different medical and developmental concerns. Common features include learning support needs, speech delay, growth delay before and after birth, heart problems, behavioral difficulties such as concentration issues and anxiety, and subtly unusual facial features. Some individuals are unaffected carriers, discovering the deletion only after their child is diagnosed.

The features likely result from loss of multiple genes in the region. The CRKL and MAPK1 genes have been suggested to play a role in heart anomalies. MAPK1 may also be linked to placental development, premature birth, and intrauterine growth restriction, and in mice it contributes to social behavior. Very distal deletions including the SMARCB1 gene are associated with an increased risk of malignant rhabdoid tumors, though most persons with distal deletions do not have deletion of this gene.

Reader's Guide

22q11.2 distal deletion syndrome is significant as a distinct genomic disorder that highlights the complexity of chromosomal microdeletions. Its recognition as separate from 22q11.2 deletion syndrome (DiGeorge/velocardiofacial syndrome) has refined genetic diagnosis and counseling. The condition's variable expressivity—from silent carriers to individuals with heart defects, learning difficulties, and growth delay—underscores the importance of personalized medical management. Research into candidate genes like CRKL and MAPK1 offers insights into the biological pathways underlying congenital heart disease, placental function, and behavior. The association of SMARCB1 deletions with malignant rhabdoid tumors necessitates careful monitoring for affected individuals, though the risk magnitude remains poorly understood. The syndrome's de novo origin and 50% inheritance risk inform family planning discussions. Ongoing research aims to clarify the full clinical spectrum and identify all contributing genes, as many features remain unexplained. The condition serves as a model for understanding how genomic architecture—specifically repetitive DNA sequences—can predispose to recurrent rearrangements.

Did You Know?

• The first published description of a person with a 22q11.2 distal deletion was in 1999.
• Some people carry the deletion without any symptoms and only discover it after their child is diagnosed.
• The deletion is usually de novo, meaning both parents typically have normal chromosomes.
• Very distal deletions that include the SMARCB1 gene are associated with an increased risk of malignant rhabdoid tumors.

Genetic Architecture and Inheritance

The 22q11.2 deletion syndrome — historically called DiGeorge syndrome after the American physician Angelo DiGeorge who first characterized it in 1968 — traces its origin to a small missing segment on the long arm of chromosome 22. The deleted stretch, located at the 22q11.2 position, encompasses roughly thirty to forty genes clustered in the middle region of that chromosome. Because the condition follows an autosomal dominant pattern, a single copy of the affected chromosome is sufficient to produce the disorder; a second normal copy offers no protection. In approximately nine out of ten cases the deletion arises spontaneously as a new mutation during early embryonic development, meaning neither parent carries the change. The remaining ten percent of cases are passed down from an affected parent. The precise chromosomal basis was not identified until late 1981, nearly thirteen years after the syndrome's initial clinical description. Today the condition is recognized as affecting roughly one in every four thousand individuals, making it one of the more common chromosomal microdeletion disorders.

A Mosaic of Clinical Features

One of the defining challenges of 22q11.2 deletion syndrome is its remarkable clinical variability. Even siblings sharing the same deletion can present with strikingly different feature combinations, a phenomenon rooted in the syndrome's incomplete penetrance. Clinicians have long relied on the CATCH-22 mnemonic to organize the most recognizable signs: cardiac defects such as interrupted aortic arch or tetralogy of Fallot, abnormal facial features including a tubular nose and short philtrum, thymic aplasia or hypoplasia, cleft palate, and early-life hypocalcemia from underactive parathyroid glands. In newborns, the first red flags are often congenital heart anomalies or seizures triggered by dangerously low calcium. Beyond infancy, affected children frequently battle recurrent infections because T-cell–mediated immunity is compromised, sometimes by an absent or underdeveloped thymus. Additional complications span kidney malformations, significant feeding difficulties, gastrointestinal motility problems, and later-onset conditions such as hypothyroidism, low platelet counts, and autoimmune diseases. Because the symptom constellation ranges from mild to life-threatening and is so heterogeneous, early diagnosis remains difficult. A clinical suspicion based on the pattern of findings is ultimately confirmed through targeted genetic testing.

Cognitive Profile and Psychiatric Risk

The neuropsychological landscape of 22q11.2 deletion syndrome is as complex as its physical one. Children typically score in the below-borderline range on IQ assessments, with verbal abilities generally outperforming nonverbal ones. Some manage in mainstream classrooms while others require special education or home schooling. Speech and language development presents a distinct challenge: nearly 69 percent of affected children carry palatal abnormalities that produce velopharyngeal inadequacy, causing air to escape through the nose during speech and reducing intelligibility. Vocabulary acquisition is often severely delayed, and some children remain nonverbal well into their third year. Hearing loss can compound these difficulties by impairing self-monitoring of oral output. Perhaps the most sobering aspect is the syndrome's psychiatric dimension. Individuals face a twenty- to thirty-fold elevated risk of schizophrenia compared with the general population. Approximately thirty percent experience at least one psychotic episode, and roughly a quarter develop full schizophrenia by adulthood. The deletion accounts for an estimated 0.5 to 2.0 percent of all schizophrenia cases. Complicating matters further, affected adults carry a heightened risk of early-onset Parkinson's disease, a diagnosis that can be delayed by as much as ten years because antipsychotic medications used to treat psychosis can themselves produce parkinsonian symptoms.

Management, Prognosis, and the Road Ahead

No cure currently exists for 22q11.2 deletion syndrome, but a structured, multidisciplinary treatment approach can meaningfully improve quality of life by addressing the potentially numerous organ systems involved. Management is highly individualized because the severity of cardiac and immune-system involvement is the primary determinant of long-term outcomes. For children whose soft palate does not close properly during speech, interventions range from the fitting of a palatal prosthesis to surgical correction of velopharyngeal inadequacy. Heart defects may require surgical repair in infancy, while immune deficiencies call for vigilant infection monitoring and, in some cases, immunological support. Despite the breadth of potential complications, the prognosis is not uniformly grim. With appropriate and timely medical intervention, life expectancy for many affected individuals can approach that of the general population. The key variable is how severe the cardiac and thymic manifestations are; those with milder presentations and well-managed conditions tend to fare best. Ongoing surveillance remains essential, however, because late-appearing complications — autoimmune disorders such as rheumatoid arthritis or Graves' disease, psychiatric illness, and early-onset neurodegenerative conditions — can emerge decades after the initial diagnosis. The syndrome thus demands a lifelong partnership between the patient and a coordinated team of specialists.